Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jan;174:1-9.
doi: 10.1016/j.clim.2016.10.012. Epub 2016 Oct 29.

Intraperitoneal Injection of IDO-expressing Dermal Fibroblasts Improves the Allograft Survival

Affiliations

Intraperitoneal Injection of IDO-expressing Dermal Fibroblasts Improves the Allograft Survival

Mohsen Khosravi-Maharlooei et al. Clin Immunol. .

Abstract

Indoleamine 2,3-dioxygenase (IDO) is an immunosuppressive enzyme with tolerogenic effects on different immune cells. Our group has previously shown that co-transplantation of IDO-expressing fibroblasts with donor tissues can delay immune rejection by inducing local immunosuppression. In this study, we have employed a systemic approach to improve allograft survival without using any immunosuppressive medication. To achieve this, 10 million lentiviral transduced IDO-expressing donor derived fibroblasts were injected into the peritoneal cavity of allograft recipients. We showed that IDO-fibroblast therapy increases the survival of both islets and skin allografts and decreases the infiltration of immune cells in subcutaneous transplanted skins. Indirect pathway of allo-reactive T cell activation was suppressed more than the direct pathway. Injected IDO-fibroblasts were found in peritoneal cavity and mesenteric lymph nodes of the recipient mice. In conclusion, IDO-expressing fibroblast therapy proved to be a novel approach in improving the allogeneic graft survival.

Keywords: Allograft survival; Fibroblast; Indoleamine 2,3-dioxygenase.

Similar articles

See all similar articles

Cited by 1 article

Publication types

Substances

LinkOut - more resources

Feedback